Proteomics in Small Cell Lung Cancer
Recruiting now
Conditions studied: Small Cell Lung Cancer
In brief
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Key facts
- Study ID
- NCT05623956
- Run by
- Aalborg University Hospital
- People needed
- 50
- Starts
- 2023-03-01
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2025-01-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Written and signed informed consent
- Histopathologically and/or cytologically newly-diagnosed SCLC
- Measurable disease on CT scans
- Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide
You may not qualify if…
- Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
- Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
- Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
- Treatment with any other investigational agent
Where it is running
- Aalborg University Hospital — Aalborg, Region North Jutland, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.